Greg Pyszczymuka
Corporate Officer/Principal bei AYTU BIOPHARMA, INC.
Vermögen: 64 661 $ am 30.04.2024
Aktive Positionen von Greg Pyszczymuka
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AYTU BIOPHARMA, INC. | Corporate Officer/Principal | - | - |
| NEOS THERAPEUTICS, INC. | Corporate Officer/Principal | 01.11.2018 | - |
Karriereverlauf von Greg Pyszczymuka
Ausbildung von Greg Pyszczymuka
| Rutgers State University of New Jersey | Undergraduate Degree |
| Argosy University | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 4 |
| Frankreich | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AYTU BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
- Börse
- Insiders
- Greg Pyszczymuka
- Erfahrung
